Celldex Therapeutics
CLDX
150 hedge funds and large institutions have $2.28B invested in Celldex Therapeutics in 2013 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 46 increasing their positions, 50 reducing their positions, and 18 closing their positions.
140% more capital invested
Capital invested by funds: $949M → $2.28B (+$1.33B)
128% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 18
126% more call options, than puts
Call options by funds: $73.3M | Put options by funds: $32.4M
16% more funds holding
Funds holding: 129 → 150 (+21)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$166M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.7M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$21.6M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
+$15.4M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$57.4M |
| 2 |
HM
HealthCor Management
New York
|
-$32.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$25.3M |
| 4 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$14.8M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$14.2M |
CLDX Hedge Fund Activity: Q3 2013 in Review
150 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2013, worth a combined $2.28B — up 140% from $949M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new CLDX positions and 18 closed out — a net gain of 23 holders — while 46 added to existing stakes and 50 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $166M. The largest seller was SAC Capital Advisors, cutting an estimated $57.4M.
- 150 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2013, up from 129 in Q2 2013.
- Funds reported $2.28B of Celldex Therapeutics stock for Q3 2013, up 140% quarter-over-quarter.
- 41 funds opened new Celldex Therapeutics positions in Q3 2013 and 18 closed out, a net change of +23 holders.
- The largest Celldex Therapeutics buyer in Q3 2013 was Fidelity Investments, an estimated $166M added.
- The largest Celldex Therapeutics seller in Q3 2013 was SAC Capital Advisors, an estimated $57.4M sold.
Based on aggregated 13F filings for Q3 2013.